MediciNova has posted positive results from a study that examined the potential clinical efficacy of MN-001 for the treatment ofnonalcoholic steatohepatitis (NASH). MN-001, administered orally once daily (10, 30, and 100 mg/kg) for three weeks, was evaluated in the STAM mouse model of NASH, as measured by liver biochemistry and histopathology, NAFLD activity score (NAS), and percent of fibrosis and gene expression. MN-001, in a dose-dependent manner, significantly reduced fibrosis area compare...